CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
CordenPharma›
Library
CordenPharma

CordenPharma

CordenPharma is a full-service CDMO developing and manufacturing APIs, drug products, and lipid excipients for pharmaceutical and biotech companies.

Basel, CH🇨🇭
Founded
2006
Loading
Overview
M & A
Compare
Employees
News
Library

CordenPharma - Library

cordenpharma.com·Crawled Oct 9, 2026·

Topics

Publication type

Content origin
Row density

Product

6 pages
  1. DCAT 2026: Sterile Injectable Drug Product Capacity Expansions/learn-about-injectable-drug-product-manufacturing-at-dcat-2026

    Schedule a meeting at DCAT 2026 about aseptic fill & finish sterile injectable manufacturing capacity expansions from clinical to commercial.

  2. Facilities Network | Our cGMP Facilities/how-we-deliver/facilities-network

    CordenPharma's integrated facility network across Europe and the US provide flexible contract manufacturing of APIs & Drug Producs with GMP compliance.

  3. Integrated CDMO APIs, Drug Product & Lipids/what-you-need/integrated-supply

    CordenPharma CDMO provides integrated supply of APIs, Drug Products, Lipids & LNPs for the development & manufacture of complex modalities at all stages.

  4. Pharma Project Management | CDMO/how-we-deliver/project-management

    CordenPharma's Project Management team ensures aligned API, Drug Product & Lipid process development, analytical, quality and compliance expertise.

Blog

6 pages
  1. CordenPharma Chenôve Attracts Top Pharma Talents/articles/cordenpharma-chenove-attracts-top-talent-in-the-pharmaceutical-industry

    Chemistry is a high-tech science. CordenPharma Chenôves attracts pharma talent who love science and want to industrialize it.

  2. CordenPharma Signs Multi-Year Peptide Manufacturing Agreement/articles/cordenpharma-signs-multi-year-agreement-for-manufacturing-of-a-commercial-peptide

    Press Release 10-1-2023: CordenPharma signs multi-year agreement for the contract manufacturing of a large-volume commercial peptide.

  3. DCAT 2026: Peptide Manufacturing for FIH Clinical & Commercial/learn-about-peptide-drug-substance-manufacturing-at-dcat-week-2026

    Schedule a meeting with CordenPharma at DCAT 2026 about our peptide API CDMO supply from small-scale to FIH clinical & commercialization using SPPS & TAPs.

  4. DCAT 2026: Small Molecule APIs & Drug Product CDMO Services/learn-about-small-molecule-drug-substance-drug-products-at-dcat-week-2026

    Schedule a meeting with CordenPharma at DCAT 2026 to discover our broad Small Molecule Drug Substance & Drug Product capabilities

Press

6 pages
  1. CordenPharma Celebrates 20 Years of CDMO Partnership in 2026/cordenpharma-celebrates-20th-anniversary-in-2026-powered-by-teamwork

    2026 is CordenPharma’s 20th Anniversary! Our passion for science, dedication to innovators and their patients, and CDMO innovation is powered by teamwork.

  2. CordenPharma LNP Summit: Targeted Nanoparticle Drug Delivery/lnp-summit-2025

    CordenPharma LNP Summit - Sept 9 2025: experts discussed extra-hepatic & targeted nanoparticle Drug Delivery & CDMO LNP Formulation scale-up.

  3. Events & Pharma Trade Shows | Media Hub/media-hub/events

    Stay informed about pharmaceutical trade show exhibits such as CPHI and sponsored presentations given by CordenPharma scientists on our events page.

  4. Media Hub/media-hub

    Stay informed on CordenPharma's latest news, events and resources.

Careers & Hiring

4 pages
  1. Careers/careers

    Join CordenPharma's team of pharma professionals, where every job matters. Our work environment fosters diversity, inclusion & personal career development.

  2. Hiring Pharma CDMO Jobs Basel Switzerland I CordenPharma/hiring-pharma-manufacturing-jobs-in-basel-switzerland

    CordenPharma is hiring engineers, operators and supply chain managers for pharma CDMO jobs near Basel, Switzerland. Join us on our journey to new heights!

  3. Hiring Pharma CDMO Jobs in Boulder, CO (US) I CordenPharma/careers/hiring-pharma-manufacturing-jobs-in-boulder-colorado

    CordenPharma is hiring engineers, operators and supply chain managers for peptide pharma jobs in Boulder, Colorado. Join us on our journey to new heights.

  4. Opportunities | Careers/careers/opportunities

    Explore the many pharmaceutical job and career opportunities available at CordenPharma. Join our global team to make a difference in the lives of patients.

Team

3 pages
  1. Florian Hochstatter, Author at CordenPharma/author/florian
  2. Our Team | About Us/about-us/our-team

    Meet the CordenPharma Executive Leadership team driving our organization of expert professionals with extensive experience in the pharmaceutical industry.

  3. Technology & Science Advisory Board (TSAB)/about-us/technology-science-advisory-board

    CordenPharma Technology & Scientific Advisory Board consists of: Dr. Chantal Pichon, Dr. Olivia Merkel, Dr. Jean-Christophe M. Monbaliu,, Dr. Roderich D. Süssmuth & Dr. Karl Wagner.

About

6 pages
  1. About Us/about-us

    CordenPharma is a full-service CDMO for the global market, providing expert support for the development and manufacturing of APIs, Excipients, Drug Products, and associated Packaging Services.

  2. Company Culture | About Us/about-us/our-culture

    CordenPharma culture is built on values of integrity, accountability, trust, collaboration & reliability with a focus on diversity, career growth & ESG.

  3. Mission & Vision | About Us/about-us/our-mission-and-vision

    CordenPharma's mission & vision is to support global Pharmaceutical & Biotechnology customers with high-quality products for the well-being of patients.

  4. Quality | About Us/about-us/quality

    CordenPharma's comprehensive quality management systems ensure our global cGMP facilities are fully compliant with the highest level of patient safety.

Homepage

1 page
  1. Homepage/

    CordenPharma is a leading CDMO for cGMP development & manufacturing of APIs, lipid excipients, drug products, injectables, peptides, LNPs, oligos, & osd.

Coverage

5 items
  1. CordenPharma South Carolina Peptide Expansion Groundbreaking| CordenPharmacordenpharma.com/articles/cordenpharma-south-carolina-celebrates-groundbreaking-of-major-expansion-to-advance-us-peptide-manufacturing/

    CordenPharma South Carolina marks the groundbreaking of a major expansion for U.S. peptide manufacturing, with South Carolina Governor Henry McMaster joining the celebration. The expansion represents a $200 million investment to advance peptide manufacturing in the United States. The groundbreaking celebration takes place on September 22, 2026.

    Sep 2026 · CordenPharmaNews article

  2. CEO to Transition from Michael Quirmbach to Jean-Luc Herbeauxcordenpharma.com/articles/press-release-cordenpharma-appoints-dr-jean-luc-herbeaux-as-chief-executive-officer-to-lead-next-phase-of-growth/

    CordenPharma appoints Dr. Jean-Luc Herbeaux as chief executive officer, effective October 1, 2026. Dr. Michael Quirmbach transitions from CEO to board member and senior advisor.

    Sep 2026 · CordenPharmaNews article

  3. Aseptic Fill-Finish Injectable Capacity Boosts to 500M Units / Yearcordenpharma.com/articles/press-release-cordenpharma-boosts-aseptic-fill-finish-capacity-to-500-million-sterile-injectable-units-per-year/

    CordenPharma is increasing its sterile injectable manufacturing capacity to 500 million units per year. The CDMO says a multi-year investment of €80 million will fund a new facility and additional aseptic fill-and-finish lines.

    Sep 2026 · CordenPharmaNews article

  4. CordenPharma Closes Acquisition of Peptide CDMO AmbioPharmcordenpharma.com/articles/cordenpharma-closes-acquisition-of-peptide-cdmo-ambiopharm/

    CordenPharma completes its acquisition of peptide CDMO AmbioPharm. AmbioPharm has sites in South Carolina, United States, and Shanghai, China.

    Aug 2026 · CordenPharmaNews article